Biotech Peptides Appears in 31.3% of AI Answers. Here's Our Five-Step Plan to Improve Its AI Visibility.
This report supports CiteWorks Studio's examination of how AI search is recommending Peptide Suppliers. For more detail, you can also read Peptide Suppliers: AI Visibility Discovery Index.
On this report
Browse sections
- Answer Capsule
- Current AI visibility
- What changed since last month
- Next Step
- Step 1. Measure
- Step 2. Make the website consistent
- Step 3. Align the external narrative
- Step 4. Optimize priority company pages
- Step 5. Publish around buyer questions
- Our 90-day action plan
- Methodology
- Our first three priorities
- Related research
- Learn More
Key Takeaways
- Biotech Peptides appears in nearly a third of benchmark AI answers and is recommended in about one fifth, but it trails the category leader on first-place placements.
- The report establishes a new baseline, so the November 2026 results should be treated as a reference point rather than a month-over-month trend.
- No conflicting claims were recorded in the captured answers, but the company still needs fact checks against primary sources before page edits or publisher requests.
- The homepage carries most citations, while product pages contribute little, suggesting a need for clearer page-level facts and content built around common buyer questions.
Answer Capsule
In November 2026, Biotech Peptides appeared in 142 of 453 AI answers included in the Peptide Suppliers benchmark (31.35%). It received 91 recommendations (20.09%), with 70 Top 3 placements and 28 first-place recommendations. A mention means the company appeared in an answer; a recommendation means the answer affirmatively endorsed it.
Our plan compares the company with its competitors, checks conflicting AI claims against reliable sources, and identifies website pages, third-party sources and buyer questions to address. This edition establishes a research baseline. It does not claim a change from earlier editions measured on a different basis. Conflicting AI claims require verification before corrections are proposed.
Current AI visibility
Questions This Section Answers
- How do Biotech Peptides mentions, recommendations and placements compare with its Peptide Suppliers peers?
Biotech Peptides recorded 142 mentions (31.35%) and 91 recommendations (20.09%) across 453 answers included in the benchmark. Top 3 placements numbered 70; first-place recommendations numbered 28. Framing among its mentions was 95 positive, 47 neutral and 0 negative.
Rank | Company | Mentions | Mention rate | Recommendations | Recommendation rate | Top 3 | Top 3 rate | #1 | #1 rate |
|---|---|---|---|---|---|---|---|---|---|
1 | Phoenix Pharmaceuticals | 178 | 39.29% | 117 | 25.83% | 94 | 20.75% | 58 | 12.80% |
2 | Biotech Peptides | 142 | 31.35% | 91 | 20.09% | 70 | 15.45% | 28 | 6.18% |
3 | Core Peptides | 152 | 33.55% | 72 | 15.89% | 59 | 13.02% | 17 | 3.75% |
4 | AminoVault | 33 | 7.28% | 27 | 5.96% | 17 | 3.75% | 5 | 1.10% |
5 | Peptides Source | 10 | 2.21% | 4 | 0.88% | 3 | 0.66% | 1 | 0.22% |
6 | Blue Sky Peptide | 36 | 7.95% | 3 | 0.66% | 3 | 0.66% | 0 | 0.00% |
7 | Peptide Tech | 7 | 1.55% | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% |
Biotech Peptides sits near the top of this field: it appears in roughly a third of the benchmark answers and carries an endorsement in about a fifth. That is a strong position, but the gap to the leader is real, and the company earns fewer first-place finishes than its overall presence would suggest.
The practical reading is that Biotech Peptides is widely known to these AI services but not always the preferred answer. The agency would build a scorecard that separates presence from endorsement, so the client can see where it is competitive and where it is merely listed.
Because this edition sets a new baseline, these figures describe one selected sample rather than a trend. The agency would treat them as a starting reference and re-measure on the same scope before drawing conclusions about movement.
What changed since last month
Questions This Section Answers
- How did Biotech Peptides counts and coverage differ across the available monthly snapshots?
Metric | Nov 2026 |
|---|---|
Mentions | 142 / 453 (31.35%) |
Recommendations | 91 / 453 (20.09%) |
Top 3 recommendations | 70 / 453 (15.45%) |
#1 recommendations | 28 / 453 (6.18%) |
Only months with verified results are shown. Monthly sample coverage is listed in Methodology.
This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.
This month's results are the first on the broader question set, so they stand alone rather than continuing an earlier series. The earlier editions used a narrower scope and remain in the archive; comparing them with this month would mix two different samples.
The observed totals describe this selected sample only. A different answer total between editions does not establish why counts or rates moved, and the agency would not present the change as performance.
What the client gains is a stable reference point. The agency would lock the question scope now so that future editions can be compared like for like, and would flag any scope change before it is made.
AI recommendation trend
Observed recommendation rate (%), Nov 2026
- Biotech Peptidesno changeNov 202620.09%
Separate selected monthly samples. Missing points are unavailable, not zero. Provider/prompt equivalence is unverified; rate movement does not demonstrate causation.
/ Take the next step
Want to Understand Your AI Citation Footprint?
We start every engagement with a full audit of how AI systems reference your brand today.
Measurable, Repeatable Programme
Build a durable foundation of credible citations that compounds over time and continues to influence AI answers as new queries emerge
Citation Architecture Review
Identify which high-authority community sources are and aren't working in your favour across AI platforms.
AI Visibility Audit
Understand exactly how LLMs are referencing your brand today and which sources are shaping those answers.
Step 1. Measure
Questions This Section Answers
- What should the agency measure and verify first for Biotech Peptides?
AI answers contained 0 conflicting claims about Biotech Peptides: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.
No conflicting claims about Biotech Peptides were recorded in the captured answers, so there is nothing urgent to correct. That is a clean starting position, though it reflects the answers reviewed rather than a guarantee that every statement elsewhere is accurate.
The useful work now is comparative. The agency would set the company's presence and endorsement figures against the other named suppliers, so the client can see which competitors are ahead and on which measure.
Alongside that, the agency would assemble a short list of company statements worth checking against primary sources. A zero-conflict result lowers the priority but does not remove the value of confirming key product and company facts.
Step 2. Make the website consistent
Questions This Section Answers
- Which recorded claim differences about Biotech Peptides should be verified before proposed page edits?
No results are available for this part of the analysis.
Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.
No disputed topics were supplied for this part of the analysis, so there is no claim to adjudicate here. The agency would not invent one; instead it would confirm which company statements matter most and check them against the client's own verified sources.
Where a question does arise, the first step is to resolve the entity, the date and the source. Different dates can make two statements look contradictory when they are not, and a company name can match more than one business.
Only after that check would the agency propose a page brief. Any correction would rest on current primary-source verification, and ambiguous matches would stay out of the queue.
Step 3. Align the external narrative
Questions This Section Answers
- Which cited third-party pages are relevant to fact review for Biotech Peptides?
Cited page selected for review | Citation appearances in all captured answers | Answers mentioning the company | Conflicting claims linked to this page |
|---|---|---|---|
https://americanpeptides.us/ | 55 | 19 | 0 |
https://biosynth.com/peptides | 51 | 15 | 0 |
https://phoenixpeptide.com/product_category/peptides/ | 64 | 13 | 0 |
https://pspeptides.com/ | 21 | 13 | 0 |
https://rpeptide.com/products/peptides/ | 28 | 9 | 0 |
https://genscript.com/catalog-peptides.html | 30 | 8 | 0 |
These pages were selected because they relate to the company in the captured answers. Their current contents still need checking before any correction request. A page linked to a conflicting claim is not necessarily its cause, and the same answer may contribute to more than one row.
The cited pages listed for review are mostly third-party peptide and supplier sites, and none carries a conflicting claim about Biotech Peptides. Their appearance in captured answers does not establish that any of them shaped those answers.
The agency would check each page's current contents before proposing anything, since a citation alone says nothing about influence. Where a page genuinely misstates a verifiable fact, the agency would prepare an evidence-backed request; where it does not, the outcome is a documented no-change decision worth recording.
Step 4. Optimize priority company pages
Questions This Section Answers
- Which observed Biotech Peptides website pages should receive review briefs?
Company website page | Citation appearances in all captured answers | Benchmark answers citing the page | Recommending answers citing the page |
|---|---|---|---|
https://biotechpeptides.com/ | 46 | 46 | 27 |
https://biotechpeptides.com/product/cjc-1295-ipamorelin-10mg-blend-2/ | 5 | 5 | 1 |
https://biotechpeptides.com/product/ipamorelin-5mg/ | 4 | 4 | 1 |
https://biotechpeptides.com/product/ll-37-5mg/ | 4 | 4 | 2 |
https://biotechpeptides.com/about/ | 3 | 3 | 0 |
https://biotechpeptides.com/buy-peptides/ | 2 | 2 | 0 |
https://biotechpeptides.com/product/cjc-1295-dac-5mg/ | 2 | 2 | 2 |
https://biotechpeptides.com/product/kisspeptin-10-10mg/ | 2 | 2 | 2 |
The company's website was cited 85 times across 24 distinct page addresses; the table shows 8 pages selected for review. Zeros in the answer columns mean no matching answers were recorded. A cited page is not automatically a page that accompanied a recommendation.
The company's own site is by far its most-cited property, with the homepage carrying most of that weight. Product pages appear far less often, and the about and buying pages barely register in the captured answers.
That pattern suggests the homepage is doing the heavy lifting while individual product pages contribute little to how these services describe the company. The agency would write page briefs that give each priority product page a clear, factual identity rather than leaving the homepage to speak for everything.
Briefs would draw only on approved company facts and would be checked against what each page currently says before any edit is proposed.
Step 5. Publish around buyer questions
Questions This Section Answers
- Which observed buyer questions support content briefs for Biotech Peptides?
Question observed in the research | Benchmark answers to this question | Company mentions | Company recommendations |
|---|---|---|---|
What are the best peptide companies in the US? | 4 | 3 | 3 |
What are the best peptide shops? | 3 | 3 | 3 |
What are the most popular peptide brands? | 4 | 2 | 2 |
What is the best company to buy peptides from? | 3 | 2 | 2 |
What is the best peptide company in the USA? | 2 | 2 | 2 |
What is the best peptide company out there? | 4 | 2 | 2 |
What is the best peptide company to buy from in the USA? | 3 | 2 | 2 |
What is the best rated peptide company? | 3 | 2 | 2 |
These are recorded answer observations, not search volume, verified demand, or proof of missing website content.
The recorded questions are almost all variations on which peptide company is best, and Biotech Peptides appears in most of the answers to them. That is a narrow set of questions, so the agency would not read it as broad buyer demand.
The opportunity is to publish content that answers the questions buyers actually ask about products, sourcing and quality, using approved facts. Before proposing any new page, the agency would check whether existing pages already cover the topic.
Where coverage is missing, a brief would set out the question, the approved answer and the evidence behind it, so the page can be reviewed and published without guesswork.
Our 90-day action plan
Questions This Section Answers
- How should the agency sequence the proposed Biotech Peptides work and judge completion?
Period | Deliverable | Completion criterion |
|---|---|---|
Days 1–30 | Baseline scorecard, scoped fact-review register and page/source shortlist | Each record has an owner, evidence requirement and review status |
Days 31–60 | Approved page briefs and justified publisher requests | Separate confirmed edits, no-change decisions, requests and responses |
Days 61–90 | Buyer-content briefs and a fresh scorecard | Record work completed separately from measured answer outcomes and comparability limits |
The first month establishes the working base: a scorecard, a scoped fact-review list and a shortlist of pages and sources, each with an owner and a review status. Nothing is corrected in this phase; the aim is a clear, evidenced starting position.
The second month turns confirmed findings into page briefs and, where justified, publisher requests. Confirmed edits, no-change decisions, requests and responses are recorded separately so the client can see exactly what was done.
The final month adds buyer-question content briefs and a fresh scorecard. Completed work is reported apart from measured answer outcomes, and no gain is claimed until a comparable measurement supports it.
Methodology
Questions This Section Answers
- How are Biotech Peptides answer metrics and citation populations defined?
This report covers 2026-11. The exact dates when the original AI answers were collected have not been verified. The visibility rates use 453 answers that met the benchmark's inclusion rules. A company is recommended only when the answer both endorses it and uses positive wording. Top 3 and first-place counts are part of those recommendations, not extra recommendations.
An answer can mention or recommend several companies, so company counts cannot be added to find the number of distinct answers. The net sentiment score is positive minus negative mentions, divided by all company mentions; it describes answer wording, not customer satisfaction.
The wider citation analysis covers 554 captured answers and 3581 appearances of cited URLs. Citation appearances across all captured answers differ from the number of benchmark answers citing a page and the number that also recommend a company. The current contents of cited pages and disputed company claims still need independent verification.
Monthly sample coverage:
Reporting month | Answers included | AI services covered | Services |
|---|---|---|---|
Nov 2026 | 453 | 6 | ChatGPT, Copilot, Gemini, Google AI Mode, Google AI Overviews, Perplexity |
Earlier editions (July 2026, August 2026, September 2026 and October 2026) used a narrower set of questions. This edition includes all captured answers screened as relevant and establishes a broader baseline. Earlier figures remain in the archive; they are not used to claim a change in performance.
Future editions using the same screening scope can be compared against this baseline.
The benchmark covers a defined set of answers that met inclusion rules, and the collection dates for the original answers have not been verified. Rates describe answer wording, not customer behaviour, and a company can appear in several answers, so counts are not additive.
Citation figures come from a wider set of captured answers and are not the same as benchmark answers that recommend a company. Cited pages and disputed claims still need independent checking.
Earlier editions used a narrower question set, so this month is a new baseline rather than a continuation.
Our first three priorities
First, confirm the facts. The agency would check the company's core product and company statements against primary sources and record each as confirmed, corrected or left unchanged, so later content rests on verified ground.
Second, strengthen the product pages. The homepage carries most citations while individual product pages contribute little, so briefs for the priority products would give each a clear factual identity drawn from approved information.
Third, build buyer-question content around the recorded questions, checking existing coverage first. Throughout, the agency would keep completed work separate from measured visibility and re-measure on the same scope before claiming any change.
Related research
This report supports CiteWorks Studio's examination of how AI search is recommending Peptide Suppliers. For more detail, you can also read Peptide Suppliers: AI Visibility Discovery Index.
/ Learn More
Understanding AI search visibility.
AI search experiences create answers by pulling information from many places online and summarizing it into a single response.


